terconazole has been researched along with bay h 4502 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Harwood, HJ; Hoover, DJ; Lawton, MP; Mankowski, DC; Treadway, JL | 1 |
| Abbott, AB; Odds, FC; Webster, CE | 1 |
2 other study(ies) available for terconazole and bay h 4502
| Article | Year |
|---|---|
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
Topics: Amides; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Humans; Indoles; Models, Molecular; Oxidoreductases; Quantitative Structure-Activity Relationship; Sterol 14-Demethylase | 2007 |
Antifungal relative inhibition factors: BAY l-9139, bifonazole, butoconazole, isoconazole, itraconazole (R 51211), oxiconazole, Ro 14-4767/002, sulconazole, terconazole and vibunazole (BAY n-7133) compared in vitro with nine established antifungal agents.
Topics: Antifungal Agents; Aspergillus; Candida; Clotrimazole; Econazole; Imidazoles; In Vitro Techniques; Itraconazole; Ketoconazole; Miconazole; Morpholines; Triazoles | 1984 |